KIRKLAND, Wash., Aug. 7 ProteoTech Inc. (ProteoTech) todayannounced that it has completed regulatory Investigational New Drug (IND)requirements and has been cleared by the FDA to initiate its Phase 1 humanclinical trial on Exebryl-1(R), a novel small molecule drug targeting toxicbeta-amyloid protein accumulation for the treatment of Alzheimer's disease.ProteoTech initiated its Phase 1 human trial on July 29, 2008.
At the 2008 International Conference on Alzheimer's disease in Chicagolast week, ProteoTech presented remarkable efficacy data in Alzheimer'stransgenic mice, whereby Exebryl-1(R) lowered brain beta-amyloid protein loadby greater than 30-50%, correlating with marked improvements in memory inthese animals. Toxic and insoluble beta-amyloid protein accumulation isbelieved to be an important part of the disease progression and memoryimpairment observed in all patients with Alzheimer's disease. Data was alsopresented demonstrating oral bioavailability and blood-brain-barrierpenetration of Exebryl-1(R).
Exebryl-1(R) is a novel small molecule drug developed at ProteoTech fromits unique library of small molecule compounds designed to target specificamyloid diseases. Over six years of pre-clinical in vitro and in vivo testingled to the development of Exebryl-1(R) that is believed to preventbeta-amyloid protein formation, deposition, and accumulation at all stages ofthe disease progression. In addition, Exebryl-1(R) also contributes to areduction and clearance of beta-amyloid protein deposits already existing inthe brain as shown by a significant and marked reduction in brain amyloidplaques in older Alzheimer's transgenic animals.
Initial studies suggest that Exebryl-1(R) may also have an important dualcapacity by inhibiting and reducing tau protein from forming paired helicalfilaments, important in neurofibrillary tangle formation. The presence ofneurofibrillary tangles in brain containing tau protein is an importantpathological hallmark of Alzheimer's disease. Further studies are ongoing toconfirm these exciting findings. Thus, Exebryl-1(R) may be the first orallybioavailable small molecule drug that affects both amyloid plaque andneurofibrillary tangle accumulation, the two major characteristic andpathological lesions of Alzheimer's disease.
About ProteoTech: ProteoTech is a private drug development Company foundedin 1996 that is a world-leader in therapeutics and diagnostics targetingamyloid diseases. With over 165 patents in its intellectual property estate,ProteoTech is in human clinical trials for its orally active small moleculedrug Exebryl-1(R) for the treatment of mild-to-moderate Alzheimer's disease.The Company is in late stage pre-clinical development with Synuclere(TM) forthe treatment of Parkinson's disease, and Systebryl(TM) for the treatment ofSystemic Amyloidosis. ProteoTech is also in late stage pre-clinicaldevelopment for a novel small peptide called PeptiClere(TM) as a nasal sprayfor the treatment of Alzheimer's disease. Lastly, ProteoTech is developing anovel small molecule compound for the treatment of amyloidosis associated withtype 2 diabetes. For further information, go to http://www.proteotech.com orcontact Steve Runnels, CEO at firstname.lastname@example.org.
SOURCE ProteoTech Inc.